Operating revenue grew by 16% on the year to RON794 million and debts by 12% on the year to RON826.6 million in the first six months of 2026.
The company’s main shareholders are Progresso Investments, with a 31.2% stake, ADD Pharmaceuticals, with 17.8%, and Rimia Investments Limited, with 14.1%, all based in Nicosia (Cyprus).
RPH shares have gained 26% over the last year, amid deals worth RON4.3 million.